top of page
Search

PFIZER, MODERNA, AND NOVAVAX ARE PREPARING FOR THE ROLLOUT OF COVID VACCINE IN THE AUTUMN

The US FDA advised Pfizer, Moderna, and Novavax in June 2023 to develop vaccines targeting the omicron subvariant XBB.1.5, which allegedly has been the most immune-evasive Covid variant so far. That particular strain was reportedly responsible for nearly 40% of all Covid cases in the US in early June, according to the CDC. While the CDC suggests that its prevalence is slowly declining, the FDA still deemed it necessary to create a specific vaccine for this variant.

Want to read more?

Subscribe to wwhisper.com to keep reading this exclusive post.

8 views0 comments

Comments

Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page